Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetes.

After induction IIT, metformin was superior to intermittent IIT for maintaining β-cell function and glycaemic control over 2 years. The strategy of induction and maintenance therapy to preserve β-cell function warrants exploration in early T2DM.